RDHL Live signals | Maximize Profits with Getagraph.com

BUY 97649 min ago

@ $0.562

Issued: 12 Feb 2024 @ 11:22

Return: -19.57%

Previous signal: Feb 7 - 11:41

Previous signal: Sell

Return: 4.13 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	329 184
Average Volume	1.22M
Market Cap	13.01M
EPS	$-22.40 ( 2024-03-10 )
Next earnings date	( $0 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.110
ATR14	$0.00200 (0.44%)

Volume Correlation

Long: 0.21 (neutral)

Short: 0.53 (weak)

Signal:(59.3) Neutral

Redhill Biopharma Ltd Correlation

10 Most Positive Correlations
TTCF	0.968
LNSR	0.963
VIRX	0.961
WISA	0.959
IMRX	0.957
NOTV	0.956
IMCC	0.955
SRZN	0.955
SNCE	0.954
FATE	0.95

10 Most Negative Correlations
MGI	-0.956
CCRC	-0.944
PWOD	-0.942
STIM	-0.937
NWFL	-0.935
IMMR	-0.933
ROST	-0.93
HZNP	-0.929
ACAHU	-0.924
EWEB	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Redhill Biopharma Ltd Correlation - Currency/Commodity

0.02
( neutral )

0.42
( neutral )

0.00
( neutral )

0.61
( weak )

Redhill Biopharma Ltd Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q2	2023
Revenue:	$1.80M
Gross Profit:	$990 000 (55.12 %)
EPS:	$0.190

Q1	2023
Revenue:	$3.60M
Gross Profit:	$1.99M (55.21 %)
EPS:	$20.44

Q4	2022
Revenue:	$12.80M
Gross Profit:	$4.20M (32.82 %)
EPS:	$1.070

Financial Reports:

No articles found.

Redhill Biopharma Ltd

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.